Navigation Links
Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
Date:10/22/2007

Dr. Rene Bruno Will Present on the Value of Clinical Trial Simulations to

Predict Efficacy and Survival Benefit of Anticancer Agents

MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Rene Bruno, Ph.D., managing director, Strategic Consulting Services, Europe, has been invited to speak to academics, regulators, and members of the Chinese pharmaceutical industry attending the International Symposium in Quantitative Pharmacology in Drug Development and Regulation. The symposium will be held in Nanjing China at the International Conference Hotel from October 29-31, 2007.

Dr. Bruno will join other leading experts from industry, government and academia in a scientific program that will discuss the latest methodologies in pharmacometrics, focusing on pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation in drug development, regulation and clinical applications. The symposium will also provide a forum for scientific discussion and collaborative exchange on model-based approaches in drug development. Dr. Bruno's presentation, discussing a model-based approach to support drug development in oncology, will be part of a session focusing on the theory and applications of model-based drug development. The presentation, entitled "Clinical Trial Simulations to Predict Efficacy and Survival Benefit of Anticancer Agents", will take place on October 29, 2007. Dr. Bruno also serves on the symposium's international advisory committee.

"Model-based drug development continues to grow as a value-added method for optimizing decisions in the drug development process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development is benefiting from the quantitative application of drug-disease models to simulate expected clinical responses of new compounds, to support critical program strategies and enhance study design decisions. Pharsight is pleased to participate at this important international symposium, to discuss opportunities and challenges for global drug development and approval in the rapidly-growing Chinese pharmaceutical industry, and to exchange information with industry colleagues on the strategic use of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Why companies dont get invited to the DEMO conference
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... three months ended December 31, 2016. SQI ... diagnostics company that develops and commercializes proprietary technologies and products ... ... commercial milestones achieved in fiscal 2016," said Andrew Morris ...
(Date:2/21/2017)... ... ... The medical potential of stem cells is both extensive and astounding, and ... their differentiating characteristics. Stem cells are unique as the have the potential to renew ... tissue or organic-specific cells with special functions. , Stem cell therapy in the ...
(Date:2/21/2017)... 21, 2017  Lexus, a returning partner of the Amgen ... and exclusive automobile partner of the men,s and women,s events for ... The 2017 Amgen Tour of California will ... of the best professional cycling teams in the world racing from ... four-day Amgen Breakaway from Heart Disease TM Women,s ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... to announce that it has been approved for full, active membership in the ... Dallas, Texas, was founded by Chief Executive Officer Jeff Olson in ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
Breaking Biology News(10 mins):